Tempest Therapeutics is a clinical-stage biotechnology company developing a portfolio of cell therapy and small molecule oncology products designed to treat hematologic malignancies, solid tumors, and immunological disorders. The company's pipeline includes autologous and allogeneic CAR-T therapies targeting cancer antigens, an oral small molecule for hepatocellular carcinoma, and additional programs for renal cell carcinoma and cancer prevention. Tempest operates under a capital-efficient model by retaining development and commercialization rights to most candidates while leveraging strategic partnerships and external funding—including collaborations with Factor Bioscience and Novatim for CAR-T development and National Cancer Institute funding for one small molecule program—and plans to generate revenue through milestone payments, royalties on net sales, and eventual partnerships or commercialization with collaborators.